but little retail shorts living dangerously and panning for pennies. They think they have until October. Hahahaha.
Zacks Group has given a promising Growth Style Score to Amarin Corporation PLC (NASDAQ:AMRN). This growth score is computed taking account of growth prospects and financial figures of a firm. This analysis also takes into account the technical parameters along with the major financial figures. After completing the analysis, the firm gives rating on a scale of A to F, wherein ‘F’ score is for the stocks with a poor growth potential when measured against the market growth prospects.
As per Zacks survey, Amarin Corporation PLC has a growth forecast of N/A for long-term and price target of $6.5. This target price is average of 3 stock opinions. The analysts have set a price target range of from $3.5 to $10.
There are numerous rating technologies used by brokerages to highlight their outlook on stocks. Zacks convert these ratings to place on a 1-5 scale. The investors make a buy decision if the rating is one and make a sell decision if the rating is five. Leading firm has assigned 1.5 rating on Amarin Corporation PLC stock.
Vote for Big mouth Hilary, when she is President she can do for the whole market what she did to the biotech sector. How come no one is blaming Hilary, you bunch of flamers.
If Bernie is elected will the government buy my stocks for me? What do I get for my 90%?
Do you mean "Blame Amarin Management" for avoiding another $200 million investor law suit the last few days and over the last three years dude. They are damned if they do, and damned by you if they don't. I prefer to be damned by the likes of you. Hehehe.
The way they worded the PR makes it vague whether or not the 967 th event had yet been reached. It seems to state that there is enough data to assume it has, or will be reached and that they may as well start the process. It would seem that each event has to be examined to determine whether the cause that triggered the event ( death, hospitalization, and etc.) was really related to cardiovascular disease or something entirely different. So, to say the 967 th event has occurred would be speculation until it is verified. Perhaps that explains the vagueness.
If the study can continue to completion after overwhelming at interim and Amarin can remain blinded the same thing could happen if it is found to be statistically significant although not necessarily overwhelming. Anchor was cancelled not because Vascepa failed to meet its end points but because other drugs did not show benefit after lowering Trigs. So of Amarin shows benefit they should have a good case for label expansion.
From March 2015 PR
" If the study is stopped based on overwhelming efficacy results, Amarin intends at that time to progress towards seeking approval for an expanded indication for Vascepa based on such results. Amarin is blinded to the results of the REDUCE-IT study and is planning for REDUCE-IT to continue until attainment of 100% of the 1,612 primary events which is estimated to be in 2017 with results anticipated to be published in 2018. "
You never know what COULD happen with this stock.
If the trial is stopped for futility wouldn't that justify the FDA rescinding the SPA using the good science approach that if two other drugs that lowered Trigs showed no significant benefit, I mean none, zero, zip then Vascepa surely wouldn't either ? If that is indeed the case what happens if Vascepas benefit is not overwhelming but does show significant benefit at interim in a much, much larger trial? I think Amarin would want an expanded label to offset expenses of continuing the trial to conclusion. If there is no benefit then it justifies the FDA decision, so if it does show benefit then it would justify Vascepa having an expanded label. It only makes sense. Anything, anytime can happen with Amarin since all the science says it works. I wouldn't want to be short this stock, no way Jose.
Artificially pumped up by shorts covering and longs knowing that nothing was going to be said at the CC because it is a double blinded study, Dah. You have to realize that it would again be shorted at the top and create yet another buying opportunity. It is called trading for a reason. Sheep get slaughtered by trading at the wrong times. I am just waiting for the next run up which may very well be the last. I believe in the science of Vascepa but that doesn't mean I will not take advantage of a situation. You have to be a fool to hold a short position this low in the cycle on a stock waiting on an event. Way too much risk for pennies. Don't be a tool, fool.
One day you may understand, but you aren't there yet. Thanks again tool.
Yes, thank you tools for covering and artificially pumping up the share price before interim results so I could sell high and re-enter at a much lower price and accumulate 20 % more, free shares. Keep up the good work fools. You should know better than shorting a beaten down stock at these levels especially one that has good reason to run in the future. Thank again.
Well, it all means that the emphasis on treatments is not only treatment successes but also on costs of treatment because someone other than the patient is paying for it, that being insurance companies. They will always go for the less expensive treatment. Vascepa is effective and cheap and as a matter of fact, that being said, Amarin has little to worry about generics because of patent protection and because it is realatively cheap the cap that creates with generics makes them not very profitable to manufacture and market. When taking into consideration the patents and the cost of litigation it is not worth the effort to imitate. A unique situation that will create market dominance.
From Preventive Cardiology:
"I was fortunate to have the opportunity to speak at length with Matt Perrone prior to his submitting an April 20th article on the PSCK9 inhibitors’ unexpectedly low uptake in the medical community. His piece was excellent; yet it failed to address the most salient aspect of this problem: Patients are suffering.
As I stated in my March 21st article on the same topic, the basis for the paucity of patients using these medications is not physicians’ reluctance to prescribe, or their need for outcomes data, or even their inappropriate utilization of these treatments. Instead, insurance providers are blocking patients’ access. This is what accounts for the small number of people currently taking PCSK9 inhibitors......"